Navigation Links
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Date:4/16/2008

GTI-2040, which is now known as LOR-2040. The data showed that LOR-2040 significantly improved the anticancer efficacy of an important group of cytokine immunotherapeutic agents, including interferon alpha and interleukin-2, which have been used in the treatment of solid tumors. The findings expand the potential avenues for development of LOR-2040.

"We are pleased to be able to present and discuss our findings at the AACR annual meeting", commented Dr. Aiping Young, President and CEO of Lorus. "These studies show our continued commitment to high quality preclinical research that is in-line with our ongoing clinical programs and corporate strategy".

About LOR-2040

LOR-2040 is a DNA-based drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. R2 has also been described as a malignant determinant that is elevated in a wide range of tumors, and through down regulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. Currently, LOR-2040 is in seven clinical studies, including a Phase II trial in AML, Phase I in MDS and Acute Leukemias, and five Phase I/II trials in solid tumors.

About LOR-253

LOR-253 is a small molecule compound that has shown selective and potent antitumor activity in a variety of human cancers, including colon cancer and non-small cell lung cancer, and has an excellent therapeutic window due to its low toxicity. The mode of action of LOR-253 involves the downregulation of cyclin D1, an important regulator of cell cycle progression and cell proliferation, and induction of the tumor suppressor Kruppel like factor 4 (KLF-4). Alterations in KLF-4 expression and the cyclin D1 regulatory pathway have been linked to the development of cancer.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeuti
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Research and Markets  has announced ... (Biodegradable Polymer, Food & Beverage, Personal Care & ... report to their offering. Lactic ... asymmetrical carbon atom. The main applications of lactic ... beverage, personal care product, and pharmaceutical industries. ...
(Date:8/27/2014)... 2014 “We are honored to be ... Ven Thangaraj, CEO of Radiant Sage. “We are offering ... the imaging corelab market to a different level. ... organizations to efficiently and effectively manage the massive amounts ... be analyzed and read by trained physicians. Being recognized ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture ... firms investing in the development of seed and ... eighth venture fund closed with more than $400 ... its $250 million subscription target by more than ... VIII shows the strength and potential of our ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Flagship Biosciences Announces Relocation and Expansion 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... today that Battelle, a science and technology development ... closing its,operations. Financial terms of the acquisition were ... Battelle to transition our assets. In,addition, we will ... our employees," said Leslie Williams, President and CEO,of ...
... BOULDER, Colo., Oct. 29 /PRNewswire/ - N30 Pharma ... and,commercialization of respiratory drugs that target endogenous,s-nitrosothiols, today ... NTMD ) covering the respiratory use of a ... not disclosed. "I am extremely pleased to ...
... 29 Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced ... financial results after the Nasdaq market closes on Thursday,November ... be held at 5:00,p.m. Eastern Time (2:00 p.m. Pacific ... by dialing,1-800-894-5910, (US) or 785-424-1052 (International) using the conference,ID: ...
Cached Biology Technology:Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle 2
(Date:8/27/2014)... advocates, campaigns against trans-fats have largely succeeded in ... aim at sugar for its potential contributions to ... still wrangling over the best way to assuage ... article in Chemical & Engineering News ... Chemical Society. , In the article, Stephen Ritter, ...
(Date:8/27/2014)... of Adelaide research has shown that piglets can be ... frequency. , The outcome of the study at the ... Reproduction Science , is an important finding for pig ... without loss of production. , "Sows don,t usually start ... heat after their piglets have been weaned," says Ms ...
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
Breaking Biology News(10 mins):Piglet weaning age no bar to litter frequency 2Gamblers are greedy bird-brains, University of Warwick research finds 2
... The American Society for Bone and Mineral Research (ASBMR) ... the world on bone and mineral metabolism, offering an ... new clinical treatments in bone diseases and disorders of ... being held in Baltimore, MD USA, October 4 ...
... immediately in low-resource countries, could have the potential to save ... 2015. Right now the annual global death toll ... Between 2016-2020, these innovations have the potential to save ... The ten, identified by international experts from hundreds of candidates, ...
... dioxide a common ingredient in cosmetics, food products, ... risks associated with the widely used compound. The report ... every year for the global market, appears in the ... Francesco Turci and colleagues explain that titanium dioxide (TiO2) ...
Cached Biology News:American Society for Bone and Mineral Research Annual Meeting Oct. 4-7 2Innovations save lives of mothers and children 2Innovations save lives of mothers and children 3Innovations save lives of mothers and children 4Innovations save lives of mothers and children 5Innovations save lives of mothers and children 6Innovations save lives of mothers and children 7